Welcome to our dedicated page for Intercure Ltd. news (Ticker: INCR), a resource for investors and traders seeking the latest updates and insights on Intercure Ltd. stock.
InterCure Ltd. (INCR), also known as InterCure (dba Canndoc), is a pharmaceutical cannabis company focused on GMP-certified, pharma-grade medical cannabis. This news page aggregates company announcements, press releases and market updates so readers can follow how InterCure’s vertically integrated seed-to-sale model and international partnerships develop over time.
News items commonly include financial results, where InterCure reports revenue, Adjusted EBITDA and cash metrics for periods such as full fiscal years and half years. These releases often discuss the performance of its cannabis segment, the impact of external events on operations, and the role of compensation from Israeli authorities related to war-damaged facilities.
Another major category is strategic transactions and partnerships. InterCure has announced the strategic acquisition of Botanico Ltd. (ISHI), a premium medical cannabis technology and brand company with partnerships with leading American cannabis operators, and a strategic investment and collaboration with Cannasoul R&D Ltd. focused on evidence-based cannabis therapeutics. Additional news covers the expansion of its partnership with the Cookies brand into Germany and other European markets, as well as agreements to cultivate, manufacture, import and distribute branded products through EU-GMP facilities and licensed pharmacies.
Corporate governance and financing developments also appear in the news feed, such as changes in board leadership, private placement financings, loans from Israeli banks and participation in industry conferences. For investors and observers tracking the pharmaceutical cannabis sector, this page provides a centralized view of InterCure’s operational updates, strategic moves and regulatory disclosures over time.
InterCure (NASDAQ: INCR) has announced the acquisition of key assets from Cannomed, including 55% of Max Pharm, 100% of a pharmacy awaiting licensing, and 51% of a patient support center. This strategic move enhances InterCure's distribution channels amid a 4% monthly growth in medical cannabis patients in Israel. The partnership will also launch an innovative e-commerce platform for medical cannabis products. This acquisition aligns with InterCure's consolidation strategy in the Israeli medical cannabis market and is expected to strengthen its position and profitability.
InterCure Ltd (NASDAQ: INCR) has officially started trading on Nasdaq, marking a significant milestone for the company, which is recognized as a leading cannabis operator outside North America. The shares will also continue trading on the Toronto Stock Exchange and Tel Aviv Stock Exchange.
Chairman Ehud Barak emphasized the listing would enhance investor access and accelerate business growth. CEO Alexander Rabinovitch stated the company is the fastest growing and profitable cannabis firm globally outside North America, reporting a record Q2 '21 revenue growth of 4 times year-over-year.